Abstract 1683P
Background
Myeloproliferative neoplasms (MPN) are chronic haematological malignancies including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET). People with MPN require proper education to confidently manage their health at home. If they develop high levels of self-care confidence, they might be more capable of performing self-care behaviours and improving their quality of life. This study aims to preliminary assess the self-care confidence of MPN patients and its association with their quality of life.
Methods
This is a descriptive cross-sectional study conducted by the Italian Association of MPN Patients (AIPAMM). Preliminary data from 9 haematology centres in Italy were analysed. During their outpatient visit, patients with MPN were given a paper-and-pencil questionnaire to measure self-care confidence using the Self-Care Confidence Scale, symptom burden using the MPN-SAF TSS, and quality of life using the EORTC QLQ-C30.
Results
The study included 292 adult patients with MPN (55% male; mean age = 60 years ± 14). They were diagnosed with MF (42%), ET (30%), or PV (28%). The most burdensome symptoms were fatigue, problems with concentration, abdominal discomfort, and inactivity. Participants rated their overall quality of life as 69.5 ± 22.8 (range 0-100). The mean level of self-care confidence was 77.4 ± 16.3 (range 0-100). We found that a higher level of self-care confidence is associated with lower symptom burden (r = -.24; p <. 001) and greater quality of life (r =. 30; p <. 001).
Conclusions
This study revealed that enhancing self-care confidence in MPN patients can decrease their symptom burden and improve their quality of life. Health professionals should educate and support people living with MPN in performing self-care behaviours to enhance their ability to manage their health at home and their level of confidence. In particular, patients should be empowered to utilize suitable strategies to address fatigue and problems with concentration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11